Search results
Author(s):
Nicholas Wettersten
,
Alan S Maisel
Added:
3 years ago
Cardiac troponin (cTn) is the core biomarker for the diagnosis of a myocardial infarct (MI).1 Indeed, as stated in Table 1, it meets all the definitions of a biomarker for acute coronary syndrome (ACS), as suggested by Maisel.2 In the setting of ACS, in addition to its diagnostic use, it is prognostic, clinically actionable and can be monitored during therapy as a surrogate of improvement. In…
View more
Author(s):
Martin Nicol
,
Mathilde Baudet
,
Alain Cohen-Solal
Added:
3 years ago
Advances in the early detection and treatment of cancer have improved overall survival in cancer patients. Nevertheless, cardiovascular diseases appear as the major cause of morbidity and mortality among cancer survivors.1 Left ventricular (LV) dysfunction and/or heart failure are the most common cardiovascular complications after administration of chemotherapies. The term ‘cardiotoxicity’ is…
View more
Evangelos Giannitsis
Job title: Assistant Professor of Medicine in Heidelberg
Author
Tobias Reichlin
Author
Author(s):
Ovidiu Chioncel
,
Sean P Collins
,
Stephen J Greene
,
et al
Added:
3 years ago
Hospitalisation is a critical event in the clinical course of heart failure (HF) and despite relatively rapid relief of symptoms, hospitalisation is followed by an increased risk of death and re-hospitalisation.1 While performance measures have been developed in the last few years with the intent of improving post-discharge outcomes, post-discharge mortality rates remain unchanged or have…
View more
Author(s):
Aniket S Rali
,
Sagar Ranka
,
Zubair Shah
,
et al
Added:
3 years ago
Coronavirus disease 2019 (COVID-19) has evolved into a global pandemic, having affected more than 2.3 million people and claiming more than 160,000 lives. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus predominantly causes fever (77–98% of cases), fatigue (52–75%) and cough (60–81%).1,2 While it primarily affects the respiratory system, it also appears to…
View more
Author(s):
Marianna Fontana
Added:
10 months ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Author(s):
Daniel E Clark
,
Sachin K Aggarwal
,
Neil J Phillips
,
et al
Added:
2 years ago
Author(s):
Antoni Bayés-Genís
,
Germán Cediel
,
Mar Domingo
,
et al
Added:
1 year ago